Patients in protracted benzodiazepine withdrawal frequently encounter a Lyme disease workup somewhere along their diagnostic odyssey. The reasons are understandable. The symptom overlap is real: fatigue, cognitive dysfunction, paresthesias, autonomic instability, muscle and joint pain, sleep disruption, and sensory hypersensitivity are common to both clinical pictures. The patient has been told their symptoms are not anxiety, imaging is normal, and the list of plausible alternative explanations is short. Lyme disease is on that short list, particularly in geographic regions where tick-borne illness is prevalent, and the workup gets ordered.
The clinical question is what that workup can meaningfully establish, and what should happen with the results. The answer is less straightforward than either side of the Lyme-disease debate usually presents, and getting it right matters: the wrong conclusion can commit a withdrawal patient to months of antibiotic treatment that does not address their actual syndrome and can, in some cases, produce its own harms.
What Is and Is Not Settled About Lyme Disease
Three clinical entities frequently get grouped under “Lyme” and benefit from being kept separate.
Acute Lyme disease is an infection with Borrelia burgdorferi (and related species) transmitted by Ixodes ticks. Diagnosis is based on the clinical picture, typically supported by serology (ELISA followed by Western blot) once the humoral response has developed. Early localized disease presents with erythema migrans in most cases and is treated with a course of doxycycline or amoxicillin. This part of the picture is not controversial.
Post-treatment Lyme disease syndrome (PTLDS) is a recognized entity in which a meaningful subset of patients treated for documented Lyme disease have persistent symptoms — fatigue, cognitive dysfunction, musculoskeletal pain — lasting six months or more after completion of standard antibiotic therapy. The Infectious Diseases Society of America recognizes the syndrome. Whether PTLDS represents ongoing infection or a post-infectious process is not fully resolved, but the bulk of evidence from controlled trials does not support prolonged antibiotic treatment as effective for it.
“Chronic Lyme disease” as used in some clinical settings refers to persistent symptoms attributed to B. burgdorferi infection in patients who may or may not have serologic evidence of exposure and who may not have had documented acute infection. This usage is contested. Mainstream infectious disease societies and guideline bodies do not recognize it as a distinct infectious entity in serologically negative patients. Other clinical groups take a broader view.
The practical consequence for a patient in benzodiazepine withdrawal is that the label “Lyme” can mean very different things depending on who applies it and on the workup findings.
The Symptom Overlap in Detail
Several symptom clusters recur in both protracted benzodiazepine withdrawal and post-treatment Lyme disease syndrome.
Cognitive dysfunction. Attention and concentration difficulties, word-finding problems, and slowed processing speed are common to both.
Musculoskeletal symptoms. Joint pain, muscle aches, and migratory discomfort are reported in both populations, though the arthritic pattern of Lyme disease — large-joint, often monoarticular, with documented effusion — is more specific when present.
Fatigue. Profound fatigue, often with post-exertional worsening, characterizes both.
Autonomic features. Palpitations, orthostatic intolerance, temperature dysregulation, and GI symptoms.
Neurologic sensations. Paresthesias, tremor, muscle twitches, and sensory hypersensitivity.
Sleep disruption. Difficulty initiating or maintaining sleep with non-restorative quality.
The overlap is wide enough that symptom profiles alone do not distinguish the two. Additional data — exposure history, serology, pattern over time — are what allow any useful separation.
When a Lyme Workup Is Genuinely Indicated
In a patient with protracted benzodiazepine withdrawal, several features shift the prior probability toward a tick-borne illness and make a serologic workup clinically reasonable.
Known tick exposure. A documented tick bite, particularly in an endemic region and particularly if the tick was attached for more than 24 hours.
History of erythema migrans. Even a remote history of a bull’s-eye rash or characteristic expanding erythema raises the prior substantially.
Characteristic early features in the history. Facial palsy, heart block, or large-joint arthritis that is not otherwise explained and was not previously attributed to Lyme.
Progressive neurologic findings. Lyme neuroborreliosis can produce radiculopathy, meningitis, and encephalomyelitis, each with specific examination and CSF findings that would not be expected in benzodiazepine withdrawal.
Geographic context. Residence in or travel to areas with high Ixodes density.
Patients without any of these features, whose symptom picture is entirely consistent with protracted withdrawal, are not well-served by a Lyme workup as the first diagnostic step. The pretest probability is low and positive results become difficult to interpret.
The Serology and Its Limitations
Two-tier testing — ELISA followed by Western blot if the ELISA is positive or equivocal — is the standard approach. The test has real limitations.
False negatives occur in early infection, before the humoral response develops. This is less relevant in a chronic symptom picture than in acute evaluation.
False positives occur with some cross-reacting infections and some autoimmune conditions.
Seropositivity in an endemic region does not establish that current symptoms are due to Lyme. A patient with remote exposure can have residual antibodies that persist for years or decades without current active infection. Interpreting seropositivity as proof of active chronic infection is where diagnostic reasoning frequently goes wrong.
Alternative testing — PCR on serum, urine antigen, CD57 lymphocyte panels, and other tests not endorsed by mainstream laboratory standards — is sometimes used by clinicians taking a broader “chronic Lyme” view. These tests have variable supporting evidence and in several cases have not been validated to the standard required for clinical decision-making. A positive result on a non-standard test in a patient whose history does not otherwise support Lyme should be treated with considerable caution.
The Risk of Getting This Wrong
Three harms follow from misattributing a withdrawal syndrome to chronic Lyme.
Prolonged antibiotic treatment, commonly for months, is sometimes recommended under the chronic Lyme framework. This carries its own risks. Fluoroquinolones, in particular, are hazardous in patients with BIND — the fluoroquinolone class can produce persistent neurologic and musculoskeletal effects of its own, and in a patient already neurologically destabilized the risk is substantial. Prolonged tetracyclines and macrolides affect the gut microbiome and have their own side effect profiles. Intravenous antibiotic regimens add line-related risks.
The underlying withdrawal syndrome is not addressed. Months spent on an antibiotic regimen for a condition that is actually protracted withdrawal is time during which the patient’s actual recovery is not being supported and during which additional pharmacologic insults are being added.
Patient resources are consumed. Chronic Lyme treatment is often expensive and not covered by standard insurance. The financial burden falls on a patient population that has usually already spent substantial resources on the workup to date.
A Reasonable Approach
For a patient in protracted benzodiazepine withdrawal considering whether to pursue a Lyme workup, a pragmatic sequence works better than either reflexive ordering or reflexive dismissal.
Review the actual exposure history and clinical features. If any of the supporting features listed above are present, proceed with standard two-tier serology.
Interpret positive serology carefully. A positive Western blot in a patient with compatible history warrants infectious disease consultation. A positive result without supporting clinical features raises the question of remote exposure rather than active chronic infection.
Be cautious with non-standard testing and with clinicians whose framework does not engage with mainstream guideline criteria. The patient’s interest is in an accurate diagnosis, which is not served by a clinical setting that produces positive diagnoses as a default.
If Lyme is excluded or not supported, return to the withdrawal framework and manage accordingly. The symptoms that prompted the workup do not become less real because Lyme was not the cause; they continue to warrant the management appropriate to their actual origin.
What the Clinical Picture Usually Shows
In clinical experience, the majority of patients in protracted withdrawal who get Lyme workups have negative or non-diagnostic results, and their symptoms continue to track with the waves-and-windows pattern characteristic of protracted withdrawal rather than with the pattern expected for tick-borne illness. In a smaller subset, serology is positive with features consistent with prior exposure, and the question becomes how much of the current picture is attributable to each condition — usually resolvable through response to treatment and the passage of time.
The condition is worth considering when the clinical features warrant it. It is not worth defaulting to when they do not. Both errors have costs, and the costs of over-attribution are higher than the costs of under-attribution in a patient whose baseline syndrome is a withdrawal picture that existing evidence already explains.